According to a recent LinkedIn post from Levee Medical, the University of Rochester Medical Center and Dr. Thomas Frye have enrolled their first patient in the ARID II IDE pivotal trial. The study is described as evaluating the Voro® Urologic Scaffold and its impact on early and long-term continence outcomes following prostate surgery.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post highlights progress in generating pivotal clinical evidence for Levee Medical’s Voro device, a key step toward potential regulatory clearance and future commercialization. For investors, successful outcomes in this IDE trial could strengthen the company’s value proposition in post-prostatectomy care and enhance its competitive positioning in the urologic devices market.